Humanigen Inc HGENQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.21
- Bid/Ask
- — / —
- Market Cap
- $23,816.03
- Volume/Avg
- 48,493 / 33,827
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.humanigen.com
Valuation
|
Metric
|
HGENQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HGENQ
|
|---|---|
Quick Ratio | 0.06 |
Current Ratio | 0.09 |
Interest Coverage | −23.36 |
Quick Ratio
HGENQ
Profitability
|
Metric
|
HGENQ
|
|---|---|
Return on Assets (Normalized) | −147.64% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
HGENQ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qypxcszybm | Fyq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dtnjhgfb | Kxdnt | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Glpzvvr | Whnzd | $97.8 Bil | |
MRNA
| Moderna Inc | Mgqczcmzn | Nrqkp | $41.3 Bil | |
ARGX
| argenx SE ADR | Nfhxwhdkf | Xmwl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dwjsryr | Lnqn | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wxncsqsrp | Ctjjhd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pjpycppk | Fjrbzm | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vnjcxrzsld | Qgztg | $12.5 Bil | |
INCY
| Incyte Corp | Jvstxhld | Lyxvf | $11.6 Bil |